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Abstract
Gestational diabetes mellitus (GDM) is a common disorder of pregnancy with short- and long-term consequences for mother
and baby. Pre-eclampsia is of major concern to obstetricians due to its sudden onset and increased morbidity and mortality
for mother and baby. The incidence of these conditions continues to increase due to widespread maternal obesity. Maternal
obesity is a risk factor for GDM and pre-eclampsia, yet our understanding of the role of adipose tissue and adipocyte biology
in their aetiology is very limited. In this article, available data on adipose tissue and adipocyte function in healthy and obese
pregnancy and how these are altered in GDM and pre-eclampsia are reviewed. Using our understanding of adipose tissue and
adipocyte biology in non-pregnant populations, a role for underlying adipocyte dysfunction in the pathological pathways of
these conditions is discussed.
Introduction
Maternal obesity (body mass index [BMI] > 30 kg/m2) is a
major public health concern which can predispose to higher
rates of adverse pregnancy outcomes, particularly the
metabolic disorders of gestational diabetes mellitus (GDM)
and pre-eclampsia [1, 2]. GDM is defined as glucose
intolerance of varying severity with first recognition during
pregnancy and is characterised by β-cell dysfunction and
exaggerated insulin resistance. Seventeen percent of live
births globally are affected by hyperglycaemia and 85% of
these have GDM [3]. GDM is associated with an increase in
pregnancy complications including antenatal disease, pre-
maturity, complicated delivery, postnatal complications,
stillbirths, macrosomia, small for gestational age babies,
congenital anomalies and neonatal mortality and morbidity.
Pre-eclampsia, a multi-system disorder particular to human
pregnancy is also a leading cause of maternal and neonatal
morbidity and mortality. It is characterised by widespread
endothelial dysfunction, resulting in hypertension due to
vasoconstriction, proteinuria attributable to glomerular
damage and oedema secondary to increased vascular per-
meability. Pre-eclampsia is a complex disease encompass-
ing different phenotypic presentations (early/late onset,
obesity-related or not, severe/mild) which may or may not
share common aetiologies. The incidence of pre-eclampsia
is 2–8% and 1.7% of pregnancies complicated by pre-
eclampsia resulted in neonatal death, 4.6% in major neo-
natal morbidity and 67% in admission to a neonatal special
care unit [4]. Women with pre-eclampsia have increased
insulin resistance leading to a metabolic adaptation to
pregnancy not dissimilar to metabolic syndrome [5]. This
may explain at least in part the link with BMI, however,
insulin resistance also predicts pre-eclampsia independent
of maternal BMI [6].
As rates of maternal obesity have been increasing so has
the incidence of these two diseases of pregnancy. The link
with maternal obesity may be related to the adverse effects
of adiposity on maternal metabolism and inflammation.
However, meta-analysis of lifestyle interventions to reduce
gestational weight gain (GWG) has shown that a reduction
in GWG does not reduce adverse pregnancy outcomes
including pre-eclampsia and GDM [7]. This suggests that
the link between maternal obesity and risk of pre-eclampsia
and GDM may not be straightforward. The aim of this
review is to use our knowledge of adipose tissue function
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and how it contributes to metabolic disease in non-pregnant
individuals to understand the pathological pathways which
may underlie adiposity-related adverse pregnancy
outcomes.
Methodology
A systemised review of adipose tissue and adipocytes in
GDM and pre-eclampsia was carried out. A search of
published literature using PubMed and MEDLINE was
conducted independently by two investigators using the
keywords: “adipose” OR “adipocyte” OR “subcutaneous
OR visceral OR omental OR ectopic NEAR fat” OR
“lipolysis” combined with “pregnancy” OR “gestation” OR
“maternal”, “gestational diabetes mellitus” OR “pre-
eclampsia” OR “hypertens* NEAR pregnancy” using the
operator AND. Duplicates were removed and all 2296
articles were screened by title and abstract for inclusion.
Articles were excluded if: BMI was the only assessment of
body fatness; there was a lack of healthy control group; an
abstract could not be found or was a conference proceeding;
only fetal outcomes were measured or the article was
published in a language other than English. The number of
total publications assessed was 176. This list was supple-
mented for the wider review with references that provided
background information on non-pregnant adipose tissue
function, healthy and obese adaptation to pregnancy and
clinical features of healthy and complicated pregnancy. A
maximum of 100 references could be cited in this article.
Non-cited reference material is available as Supplementary
References.
Adipose tissue function in healthy
non-pregnant individuals
Adipose tissue is not a single, uniform organ but is orga-
nised and distributed throughout the body into distinct
anatomical and functional depots which determine its role in
energy homeostasis and its association with disease. Adi-
pose tissues are divided into three subtypes: white, brown
and beige. Whilst brown adipose tissue has an important
role in thermogenesis and beige adipose tissue is of emer-
ging interest as a site of fat oxidation, white adipose tissue
(WAT) is the primary site of lipid storage and mobilisation
in humans and is the focus of this review. WAT acts as a
buffer against the toxic effects of excess circulating lipids
by storing free fatty acids (FFA) in adipocytes and releasing
them for use by peripheral tissues in times of relative energy
depletion. Peripheral, subcutaneous adipose tissue (SAT) is
the largest depot and is the primary storage site of fatty
acids as triglyceride. SAT can be located in the upper and
lower body; lower body SAT is more insulin sensitive and
stores fatty acids securely, whereas upper body SAT is
relatively insulin resistant and has a greater propensity to
release fatty acids from storage. Central, visceral adipose
tissue (VAT) is associated with the development of obesity-
related disorders, probably via the release of fatty acids
directly into the portal circulation. The extent and site of
lipid storage in response to energy excess is regulated by
endocrine function, the rate of lipid utilisation and the
expansion capacity of WAT.
Uptake of fatty acids is mediated via lipoprotein lipase
(LPL) that is secreted by adipocytes and situated on the
vascular endothelium of adipose tissue. LPL hydrolyses
FFA from triglycerides contained in triglyceride-rich lipo-
proteins such as chylomicrons and Very low density lipo-
protein (VLDL), allowing their uptake into adipocytes via
fatty acid transporters in the adipocyte membrane. The
release of FFA from adipose tissue is governed by lipolysis
of triglyceride, regulated via a trio of enzymes in a stepwise
manner: adipose triglyceride lipase, hormone sensitive
lipase (HSL) and monoglyceride lipase. Insulin is a key
hormone that inhibits adipocyte lipolysis and increases
glucose uptake. Healthy adipose tissue displays metabolic
flexibility, whereby lipolysis is carefully regulated by hor-
mones, catecholamines and paracrine signals to facilitate
physiological responses to changes in requirements for lipid
storage versus mobilisation. FFA released from SAT are
returned to the liver for oxidation or secretion in VLDL.
Upper body SAT is estimated to be the source of 60% of
circulating FFA, lower body SAT 15–20% and VAT
6–17% [8]. While VAT displays lower or equivalent rates
of lipolysis to SAT, it has greater responsiveness to lipolytic
stimuli and reduced responsiveness to inhibition by insulin.
Adipokines and cytokines secreted by adipocytes,
adipose-resident immune cells, endothelial cells and other
cellular compartments of the adipose tissue can have a
diverse range of autocrine and paracrine effects which act to
regulate insulin sensitivity, inflammation, cardiovascular
function, behaviour and cell growth. Adiponectin, one of
the most abundant adipokines in circulation, is anti-
inflammatory, insulin sensitising and is inversely associated
with increased adiposity. Leptin, the most well-
characterised adipokine, correlates with fat mass and is
increased post-prandially, regulating food intake and glu-
cose and fat metabolism in healthy individuals. In contrast
to adiponectin, leptin has pro-inflammatory actions and is
associated with increased adiposity and insulin resistance.
There are numerous other adipokines which are not the
focus of this current review and are discussed elsewhere [9].
Obesity is a state of chronic low-grade inflammation and
obesity-induced insulin resistance precedes macrophage
accumulation and inflammation in adipose tissue [10].
Increased accumulation of immune cells and production of
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pro-inflammatory molecules is a key mechanism by which
adipose tissue contributes to increasing insulin resistance
and dyslipidaemia. Adipose tissue may convey signals to
other tissues via the protein, lipid and microRNA content of
extracellular vesicles produced and released by adipocytes
or other cells within adipose tissue [11].
Adipose tissue expandability, insulin resistance and
cardio-metabolic disease
BMI is a universally accepted measure of body fatness and
biomarker of metabolic disease risk when used in con-
junction with other risk factors and is routinely measured in
clinical settings. However, because BMI does not measure
either the quantity or quality of body fat or convey any
information about its location (SAT or VAT), it is relatively
indiscriminate in predicting cardio-metabolic risk in com-
parison to central obesity with high intra-abdominal VAT.
BMI is thus a proxy marker of adiposity, which cannot
distinguish individuals who store fat in SAT in a relatively
benign way, from those who store fat in VAT, which is
related to metabolic dysfunction and pathology. In addition,
the site of fat storage is recognised to be influenced by
ethnicity, age, smoking and diet, which strongly suggests
that the efficacy of BMI as a risk discriminator will vary
between different populations.
Adipose tissue is comprised of adipocytes and stromal
cells including pre-adipocytes and immune cells, which
support the proliferation and differentiation of pre-
adipocytes to adipocytes and secrete a variety of cyto-
kines and growth factors facilitating this. When individuals
become obese, excess calories are stored as triglyceride
within the adipocytes of WAT. If there is insufficient
capacity in mature adipocytes, new adipocytes are formed
from pre-adipocytes in order to increase storage capacity.
The formation of adipocytes (adipogenesis) occurs in two
phases. The first phase is commitment to differentiation and
involves the production of committed white pre-adipocytes
from mesenchymal stem cells. Terminal differentiation
forms mature adipocytes containing a lipid droplet that
occupies almost all the space within the cell. In some
individuals there appears to be a limited ability to produce
mature adipocytes from pre-adipocytes (hyperplastic adi-
pocyte expansion) and instead excess fatty acids are stored
in existing mature adipocytes leading to an increase in their
size (hypertrophic expansion) [12, 13]. In obese women
hyperplasia is predominantly observed in SAT expansion,
whereas hypertrophy is observed in both SAT and VAT
adipocytes [14]. Larger adipocytes are dysfunctional and
are demonstrably insulin resistant resulting in increased
lipolysis due to resistance to the anti-lipolytic effects of
insulin [15, 16]. Healthy individuals with a family history of
type 2 diabetes mellitus (T2DM) show higher SAT diameter
compared to BMI-matched controls and SAT size is inde-
pendently correlated with insulin resistance in a variety of
populations [17]. It is not clear to what degree adipocyte
differentiation is limited by insulin resistance or whether
insulin resistance results from impaired adipocyte differ-
entiation or both. Failure of angiogenesis and the resulting
inadequate blood supply to hypertrophic adipocytes leads to
necrosis, macrophage infiltration into adipose tissue,
inflammation and dysregulated adipokine release. Increased
fibrosis is also associated with obese adipose tissue, further
contributing to limited adipocyte expandability, tissue
hypoxia and a pro-inflammatory environment.
Once SAT capacity is exceeded, lipids begin to accu-
mulate in visceral and finally ectopic tissues [13]. “Spil-
lover” of fatty acids unable to be retained in subcutaneous
adipocytes, either due to an insufficient number of mature
adipocytes or due to hypertrophic adipocytes becoming
insulin resistant, leads to an increase in the visceral fat
compartment and simultaneously a flux of fatty acids into
ectopic sites, stored as intracellular lipid droplets in tissues
such as liver, heart and pancreas. It is not the absolute
amount of fat mass per se that determines adiposity-related
risk, but it is the amount of VAT and ectopic fat accrued
which is metabolically unfavourable [18]. The formation of
ectopic fat is closely linked to the development of insulin
resistance and T2DM. Thus, individuals with limited adi-
pocyte expandability, such as South Asians, are at increased
risk of T2DM [19]. In mouse models, inhibition of adipo-
cyte lipolysis reduces both insulin resistance and ectopic fat
accumulation [20]. Thus, adipocyte dysfunction plays an
integral part in the pathological pathway of T2DM.
Maternal metabolic adaption to pregnancy and
gestational fat storage (Fig. 1A)
Adipose tissue expansion is an adaptive response to healthy
human pregnancy. Maternal body composition and meta-
bolism undergo dramatic changes in order to provide the
developing fetus with a continuous supply of nutrients and
prepare the mother for lactation. The initial phase of
gestation is anabolic when maternal fat stores increase to a
peak towards the end of the second trimester due to adi-
pocyte hyperplasia and increased adipose tissue lipogenesis.
Metabolism switches to a catabolic state around mid-
gestation, characterised by increased adipose tissue fatty
acid turnover and increased levels of lipolysis. Gluteal SAT
adipocytes increased in size and number by late pregnancy
in healthy non-obese women and adipose tissue showed
increased expression of genes involved in tissue remodel-
ing, angiogenesis and inflammation [21]. Increased rates of
lipolysis are driven by maternal insulin resistance in
response to gestational hormones, with adipocytes demon-
strating reduced insulin suppression of lipolysis in late
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pregnancy compared to early pregnancy. Animal studies
suggest there is a shift in the HSL to LPL expression ratio to
favour lipolysis [22]. Lipolysis of maternal adipose stores
accumulated in early pregnancy, coupled with reduced
glucose uptake into maternal tissues, induced by maternal
insulin resistance, ensures maximum nutrient availability
for the developing fetus. In parallel with the accumulation
of maternal adipose tissue, levels of circulating leptin in
pregnancy increase to a maximum between 20 and
30 weeks of gestation. Low plasma levels of adiponectin are
evident in pregnancy and appear to be linked to decreased
insulin sensitivity of glucose disposal rather than lipid
metabolism.
In pregnancy there is a shift in fat distribution from the
lower body towards the upper abdominal region. The
increase in abdominal fat in pregnancy has been found to be
attributable to accumulation of VAT rather than SAT and
there is an increase in VAT accumulation throughout
gestation even in healthy pregnancy. Regional differences
in SAT function were observed in pregnancy, with LPL
activity in adipocytes from the femoral region, but not the
abdominal region, increasing in pregnant women [23, 24].
Adiponectin mRNA expression does not differ between
SAT and VAT in pregnant women [25].
Maternal obesity and adipose tissue function
(Fig. 1B)
Despite lean and obese women accumulating similar
amounts of gestational fat, the distribution of adipose tissue
storage varies dependent on pre-pregnancy BMI. Skinfold
thickness measurements show that lean pregnant women
gain significantly more fat in lower body compartments,
whereas obese pregnant women gain more in upper body
Fig. 1 Adipocyte function in healthy, obese, GDM and pre-
eclampsia pregnancy. A In healthy pregnancy gestational fat storage
is accommodated by adipocyte hypertrophy. The physiologically
healthy level of insulin resistance permits controlled adipocyte lipo-
lysis in order to supply triglycerides to the fetus via placental uptake of
fatty acids from maternal VLDL. B Obese women already exhibit SAT
and VAT adipocyte hypertrophy prior to pregnancy. During pregnancy
they develop a greater degree of insulin resistance than lean women
which reduces the ability of insulin to downregulate adipocyte lipo-
lysis. This results in increased FFA flux to the liver and increased liver
VLDL production. C In women who develop GDM, it is hypothesised
that there is reduced hyperplasia and SAT hypertrophy resulting in
fatty acid spillover. These fatty acids can cascade to ectopic sites
including VAT, the liver and the pancreas and may lead to pancreatic
dysfunction β-cell failure and the development of GDM. D In women
who develop pre-eclampsia, it is hypothesised that there is an innate
maternal insulin resistance manifest in both SAT and VAT. This
insulin resistance reduces adipocyte differentiation, reducing the
number of mature adipocytes and thereby reducing the capacity of
SAT to store fat. Fatty acid spillover occurs leading to hyper-
triglyceridaemia and deposition of ectopic fat in the liver and placenta
contributing to further maternal insulin resistance and placental dys-
function. FFA free fatty acid, HSL hormone-sensitive lipase, LPL
lipoprotein lipase, SAT subcutaneous adipose tissue, VAT visceral
adipose tissue, VLDL very low density lipoprotein.
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compartments [26]. Further, lean pregnant women gain
weight at a quicker rate than overweight and obese pregnant
women, and increased VAT accumulation is found in those
who are overweight and obese [27]. VAT thickness in early
pregnancy correlates better with metabolic risk factors than
maternal BMI. VAT thickness in pregnancy has also been
found to correlate with levels of C-reactive protein and
glycated haemoglobin [28, 29]. An impaired immune
response in pregnant women, indicated by decreased
expression of CD4+ T cell cytokines, correlated with
abdominal VAT but not SAT [30].
Consistent with non-pregnant women, obesity in preg-
nancy is characterised by insulin resistance, dyslipidaemia
and low-grade chronic inflammation [31, 32]. SAT and
VAT expression of genes involved in adipocyte fatty acid
uptake were generally decreased in obese compared to lean
women in the third trimester of pregnancy [33], while others
such as fatty acid synthase were unchanged [33]. SAT and
VAT expression of genes involved in adipocyte lipolysis
and of transcription factors regulating fatty acid metabolism
(LXRα, PPARα, PPARδ, RXRα, SREBP1c) and adipo-
genesis (PPARγ) were lower in obese compared to lean
women [33]. Obese pregnant women were less able to adapt
substrate metabolism in accordance with fuel availability,
which was associated with increased postprandial inflam-
mation and insulin resistance [31, 34].
The higher levels of inflammation in obese compared to
lean women suggest that adipokines may play a role in the
pathophysiology of obesity-related pregnancy, possibly via
endothelial dysfunction [32]. There were higher levels of
leptin in maternal obesity compared to lean pregnant
women which contributed to leptin resistance [35]. Circu-
lating levels of adiponectin were significantly lower in
obese compared to lean pregnant women [31], however this
was not associated with increased levels of pro-
inflammatory cytokines [32, 36]. Hypoadiponectinemia in
late obese pregnancy was attributable to reduced expression
and methylation of the adiponectin gene [37]. When VAT
tissue explants were studied ex vivo, VAT from obese
women tended to secrete higher levels of pro-inflammatory
mediators and upon exposure to inflammatory stimuli the
tissue explants reduced the expression of genes involved in
fatty acid uptake and lipolysis [33].
Adipocyte function in lean and obese pregnancy
Adipocytes in abdominal SAT at gestational weeks 8–12
were non-significantly larger in obese pregnant women
(mean diameter 91 µm) than lean pregnant women (79 µm)
[38]. Obese women also had twice as many SAT adipocytes
as lean women in the first trimester [38]. Between the first
and third trimester, lean women significantly increased SAT
adipocyte diameter (to 87 µm) but not adipocyte number,
whereas obese women displayed no change in diameter
(87 µm in the third trimester) or number over pregnancy
[38]. There was evidence of a heterogeneous response
where, when those who had gestational weight loss were
excluded, obese women showed an increase in adipocyte
number [38]. Third trimester SAT [39, 40] and VAT [41]
adipocyte hypertrophy has also been reported in obese
compared to lean third trimester pregnant women. Others
have reported that obese women had fewer adipocytes and
increased evidence of necrosis and apoptosis suggesting a
higher adipocyte turnover and greater adipose tissue
remodelling compared to lean pregnant women [39]. Ana-
lysis of the SAT and VAT transcriptome showed that a
large number of genes in SAT had a gestational response
compared to very few in VAT [42]. There was a trend
towards lower SAT PPARγ expression in obese pregnant
women compared to non-pregnant BMI-matched controls
[43]. These data suggest that lean women undergo adipo-
cyte hypertrophy in response to pregnancy, whereas obese
women may already have adipocytes that have undergone
hypertrophy prior to pregnancy. In obese women, gesta-
tional fat gain appears to be accommodated by an increase
in cell number or increased adipose tissue remodelling.
Some have observed no difference in SAT macrophage
content between lean and obese women, and no gestational
change in either group [38]. Others have identified higher
SAT macrophage number [39] and a changed VAT mac-
rophage population composition in maternal obesity [41].
Insulin binding to SAT adipocytes was reduced by more
than 50% in the third trimester of pregnancy compared to
non-pregnant controls [40, 44, 45] and was further
decreased in obese pregnant women [40]. SAT adipocyte
lipolytic activity increased over gestation in both lean and
obese women despite obese women having a somewhat
higher lipolytic activity in early pregnancy [38]. Insulin
suppression of adipocyte lipolysis was decreased in obese
compared to lean pregnant women [40]. Similarly, while
there was no difference in adipocyte basal glucose uptake
between non-pregnant and pregnant women, there was
impaired insulin-stimulated glucose transport [44, 45] and
evidence of defective post-receptor insulin signalling in
pregnancy [44], although others disagree [45, 46]. Lower
expression of GLUT1 and GLUT4 [47] and higher
expression of IRS-2 were observed in adipocytes from
obese pregnancies compared to obese non-pregnant adipose
tissue [43] and in adipocytes from obese compared to non-
obese pregnancies although this latter observation was not
confirmed by protein expression [47]. There was also a
trend towards lower basal and insulin-stimulated lipogen-
esis in pregnant women compared to non-pregnant [44]. IL-
6 and TNFα release was not different between lean and
obese groups and was unchanged over gestation, whereas
adipocyte adiponectin release significantly declined in lean,
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but not obese, women. Adipocyte lipolysis was associated
with insulin resistance assessed by Homeostasis Model
Assessment (HOMA), in the first trimester and the pro-
portion of large adipocytes correlated with insulin resistance
in the third trimester [38].
Adiposity and risk of metabolic disorders of
pregnancy
Pre-pregnancy BMI and early GWG are potentially mod-
ifiable risk factors for gestational hypertensive disorders and
GDM [48–50]. Although BMI is a low-cost screening tool,
the limitations of its effectiveness in discriminating between
high- and low-risk pregnancy have not been formally tested.
Importantly, only ~30% of obese pregnant women have an
adverse pregnancy outcome [51]. Thus, 70 out of every 100
women identified as high risk undergo expensive, intensive
antenatal monitoring unnecessarily (Fig. 2). Consistently
GDM and PE populations can be reliably distinguished by
measures of central fatness (SAT, VAT or total abdominal
adipose tissue thickness) using ultrasonography and bioe-
lectrical impedance. VAT thickness [52] and adiponectin, a
metabolic biomarker associated with VAT [53], as well as
waist circumference [54] strongly predict GDM. Similarly,
prospective cohort studies for pre-eclampsia indicate mea-
sures of central/visceral obesity, i.e. waist circumference
[55] and VAT thickness [56] are predictive. Thus far,
large-scale multi-centre studies assessing the predictive
power of measures of adipose tissue thickness relative to
BMI are lacking and there is a lack of consensus on
appropriate risk-defining cut-offs which may be influenced
by ethnicity [19]. Recent studies also support SAT thickness
as a predictor of GDM [57] although this may be acting as a
proxy marker for visceral adiposity.
Adipose tissue and adipocyte function in GDM
(Fig. 1C)
Women with GDM had larger VAT adipocytes than normal
glucose tolerant (NGT) controls and adipocyte size corre-
lated with plasma glucose levels [58]. SAT expression of
PPARγ was reduced in GDM compared to NGT controls
[33, 43, 59] but others have found no differences in SAT or
VAT PPARγ mRNA expression between GDM and NGT.
Third trimester SAT and VAT expression of genes involved
in adipocyte fatty acid uptake were decreased in GDM
women compared to NGT women of similar BMI [33]. In
addition, SAT and VAT expression of genes involved in
triglyceride synthesis, fatty acid synthesis and triglyceride
lipolysis were decreased in GDM pregnancies compared to
NGT controls [33]. Others found alterations in expression
of VAT fatty acid binding and storage proteins, such as
perilipin 1, consistent with increased lipolysis [60].
Expression of transcription factors regulating fatty acid
metabolism were lower in GDM women compared to NGT
controls in SAT only [33].
Insulin receptor expression was found to be lower in both
SAT and VAT from women with GDM compared to BMI-
matched controls [61]. In comparative studies of non-obese
and obese insulin-controlled GDM with BMI-matched
controls, there was evidence for disruption in insulin
receptor-signalling transduction pathway in SAT of GDM.
Others have shown that defects in insulin-signalling path-
ways resided in VAT but not SAT. Neither SAT nor VAT
leptin expression was different between GDM and BMI-
matched NGT controls [62]. Many mediators have been
proposed to induce insulin resistance in adipocytes in
GDM. Plasma levels of an inhibitor of LPL, angiopoietin 4
(ANGPTL4), are decreased in GDM pregnancy [63]. In a
mouse adipocyte cell model (3T3-L1), downregulation of
ANGPTL4 expression inhibited adipocyte glucose uptake
and insulin signalling and increased expression of pro-
inflammatory cytokines [63]. VAT adipocyte plasma
membrane-associated protein (APMAP) was found to be
downregulated in GDM [64]. In the 3T3-L1 model, inhi-
bition of APMAP expression resulted in impaired insulin
signalling and activated NFκB-mediated inflammatory sig-
nalling [64]. A higher number of extracellular vesicles of
different proteomic composition were produced by VAT





















Fig. 2 Body mass index is a poor discriminator of obesity-related
adverse pregnancy outcome. Approximately 20% of all pregnancies
are in mothers who are obese at the time of antenatal booking (around
11 weeks’ gestation) and undergo expensive, intensive antenatal
monitoring. However, this percentage varies widely across different
countries. Approximately one-third of obese mothers have an adverse
pregnancy outcome. Obese mothers appear to be twice as likely to
suffer an adverse pregnancy outcome than non-obese mothers, yet
there is little information on how this varies between populations.
There are a variety of obesity-related adverse outcomes of varying
prevalence (represented by circle size). The underlying cause of
adverse outcomes in obese mothers is often linked to metabolic
dysregulation.
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extracellular vesicles from the GDM explants increased the
expression of genes involved in glucose metabolism in
placental cells [65].
In a cohort matched for BMI, VAT, but not SAT, TNFα
mRNA expression was higher in GDM compared to con-
trols, whereas IL-6 expression was unchanged in both tis-
sues [66]. Leptin secretion from SAT explants was higher in
GDM compared to NGT controls in both insulin-controlled
and diet-controlled GDM [67] but unaffected by exposure
to a variety of cytokines and hormones. SAT adiponectin
expression was lower in VAT in GDM compared to BMI-
matched controls [66]. Proteomic analyses showed in adi-
pose tissue from GDM women that there was increased
expression of inflammatory proteins and differential
expression of proteins involved in mitochondrial dysfunc-
tion, sirtuin signalling and oxidative phosphorylation com-
pared to BMI-matched NGT controls [60]. VAT, but not
SAT, from women with GDM had higher macrophage
infiltration compared to NGT controls and the degree of
infiltration correlated with systemic insulin resistance,
however these groups were not BMI-matched [68]. VAT
tissue explants from GDM compared to NGT secreted
higher levels of leptin but not IL-1β, or TNFα and others
have found increased VAT leptin expression in GDM [69].
Expression of genes that co-ordinate pro- and anti-
inflammatory pathways have been found to be altered in
VAT from GDM [70]. Apart from a higher IL-8 expression
in VAT, there was no difference in SAT and VAT mRNA
expression of pro-inflammatory IL-6, IL-6 receptor and
suppressor of cytokine signalling proteins 1 and 3 between
GDM and BMI-matched NGT controls [71]. VAT from
women with GDM showed higher expression and secretion
of angiogenic proteins such as fms-like tyrosine kinase-1
(sflt-1), fibroblast growth factor (FGF2) and endoglin than
BMI-matched controls [72]. Proteomics also revealed a
higher expression of proteins involved in extracellular
matrix in GDM VAT, suggesting a less flexible tissue
which may limit expansion [60].
Adipose tissue and adipocyte function in pre-
eclampsia (Fig. 1D)
Published data on adipocyte function in pre-eclampsia is
extremely limited. The size distribution of SAT and VAT
adipocytes was altered in pre-eclampsia with more adipo-
cytes in the lowest tertile of diameters compared to controls
suggesting limited adipocyte differentiation [73]. Women
with pre-eclampsia show systemic insulin resistance [74]
and increased whole body lipolysis [75]. In pre-eclampsia,
mature adipocytes were functionally insulin resistant as
evidenced by a reduced suppression by insulin of
β-adrenergic stimulated lipolysis [73]. Women with pre-
eclampsia have higher plasma levels of triglycerides when
compared to healthy BMI-matched controls [76] which is
evident before clinical manifestation of pre-eclampsia [77]
and suggests there may be increased rates of adipocyte
lipolysis in women who go on to develop pre-eclampsia.
Studies in placental growth factor (PlGF)-deficient mice
suggest that reduced PlGF, as is observed in pre-eclampsia
in humans, is associated with impaired adipose tissue
development and vascularisation and the development of
insulin resistance [78]. Both SAT and VAT adiponectin
mRNA expression were unaltered between control and pre-
eclampsia BMI-matched mothers [25].
In VAT, there was increased activated macrophage
infiltration in pre-eclampsia and ex vivo adipocytes isolated
from women with pre-eclampsia had higher inflammatory
cytokine release in response to a pro-inflammatory stimulus
[79]. Neutrophil infiltration was observed in the resistance
vessels of SAT of women with pre-eclampsia [80]. Expo-
sure of primary human adipocytes to human serum from
women with pre-eclampsia increased mRNA expression of
IL-6 and MCP-1 when compared to exposure to control
serum [81]. In contrast, transcriptome profiling data from
non-pregnant VAT exposed to pre-eclampsia sera suggested
that these non-pregnant adipocytes are capable of mounting
an anti-inflammatory response to the sera [82]. It was sug-
gested that in vivo adipocyte inflammation might be pro-
voked by advanced glycation end products or
lipopolysaccharide [81]. Interestingly, despite pre-
eclampsia being a disease of endothelial activation, there
was no evidence of increased expression of pro-
inflammatory endothelial activation markers in SAT from
women with pre-eclampsia [83]. However, others have
found increased expression of TNFα and ICAM-1 in SAT
from women with pre-eclampsia compared to controls [84].
Increased VAT adipocyte expression of TNFα in pre-
eclampsia has been observed and VAT adipocyte TNFα
release was inversely associated with VAT adipocyte
insulin sensitivity [79].
Evidence for ectopic fat accumulation in healthy and
complicated pregnancy
As described above, a failure of adipocyte expansion can
lead to ectopic fat accumulation and development of insulin
resistance and metabolic disease [18]. There is no evidence
of ectopic fat accumulation in healthy pregnancy [85].
There is however evidence for this pathological pathway in
pregnancies complicated by GDM and pre-eclampsia. Nei-
ther liver nor intra-myocellular fat was detected in women
with GDM using magnetic resonance spectroscopy [86].
Plasma levels of gamma-glutaryl transferase, an indirect
biochemical marker of liver fat, were predictive of GDM
[87]. Recently, the presence of non-alcoholic fatty liver
disease (NAFLD) during the initial period of gestation was
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identified as an independent risk factor for development of
GDM [88]. In women with a history of GDM, liver fat
rather than body composition was associated with insulin
resistance [89], and these women develop NAFLD later in
life [90]. There is evidence for ectopic fat accumulation in
pre-eclampsia. Classically, the disease is characterised by
atherosis of spiral arteries and the accumulation of lipids
within glomerular endothelial cells [91]. This process is
even more marked in the haemolysis, elevated liver
enzymes and low platelet count syndrome and acute fatty
liver of pregnancy, which are severe complications related
to pre-eclampsia. Elevated plasma triglycerides were
observed in pre-eclampsia [92], which is indicative of
ectopic fat accumulation [93]. There is further indirect
evidence of ectopic liver fat in pre-eclampsia as reduced
long chain polyunsaturated fatty acid synthesis was
observed in mothers with pre-eclampsia [94]. Placenta in
pre-eclampsia had a higher total and neutral lipid (trigly-
ceride and cholesteryl ester) content than in BMI-matched
controls, which is preliminary evidence suggesting that
ectopic lipid droplets may form in the placenta [95]. In
addition, epicardial adipose thickness, an ectopic site of fat
accumulation and a marker of visceral fat, was shown to
predict both PE and GDM [96–98].
Summary (Fig. 1)
Impairment of adipocyte expansion is related to develop-
ment of T2DM in non-pregnant populations and an under-
standing of this pathway sheds light on adipocyte function
in pregnancy. GWG can easily be accommodated by adi-
pocyte hypertrophy in healthy pregnancy. The relatively
limited insulin resistance induced by pregnancy hormones
in health leads to a regulated increase in lipolysis to supply
nutrients to the fetus. In obese pregnancy, women com-
mence pregnancy with a relative degree of SAT and VAT
adipocyte hypertrophy and insulin resistance. In response to
pregnancy hormones, obese women develop a higher than
normal insulin resistance which reduces the ability of
insulin to switch off lipolysis resulting in increased delivery
of fatty acids to VAT and the liver leading to increased liver
VLDL production and increased plasma triglyceride con-
centrations. There are limited data on adipocyte function in
GDM and pre-eclampsia but that which is available sug-
gests a role for adipocyte dysfunction in these diseases of
pregnancy. In women who develop GDM, one might
hypothesise that there is reduced hyperplasia and SAT
hypertrophy resulting in fatty acid spillover. These fatty
acids are directed to VAT which also experiences adipocyte
hypertrophy and a reduced ability to retain fatty acids. Once
the capacity of both depots is exceeded, then ectopic fat
may begin to collect in the liver and pancreas leading to
reduced pancreatic insulin secretion and tipping maternal
metabolism into overt GDM. In women with pre-eclampsia,
one might hypothesise that there is an innate maternal
insulin resistance perhaps induced by changes in placental
hormones secreted by a dysfunctional placenta. This insulin
resistance impairs adipocyte differentiation, limiting the
number of mature adipocytes and hence severely limiting
the capacity of SAT to store gestationally acquired fat. Fatty
acid spillover will occur, resulting in increased plasma
lipids and ectopic fat accumulation in liver and placenta
exacerbating further maternal insulin resistance and pla-
cental dysfunction. Clearly the evidence to support these
hypotheses is limited and more data that will provide an
understanding of the function of adipose tissue in GDM and
pre-eclampsia is required.
Future perspectives
Metabolic complications of obese pregnancy may share a
common metabolic origin with those found in non-pregnant
obesity, through the development of insulin resistance.
Although the concepts of benign and visceral obesity are
only just beginning to be addressed in obstetric medicine,
recognition of these obese phenotypes could have a major
impact on the ability to identify high risk pregnancy. Cur-
rently, the ability to predict the onset of gestational dis-
orders is limited, despite robust associations with BMI. A
more detailed understanding of the pathological pathways
related to adiposity may identify new risk factors to predict,
and potential new treatments to prevent, GDM and pre-
eclampsia.
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